99mTc-sestamibi uptake and histological malignancy grade in invasive breast carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 662-666

  Danielsson, Rimma ^a   Sánchez Crespo, Alejandro ^a,b   Pegerfalk, Anna ^a   Grabowska, Hanna ^c   Larsson, Stig A ^a,b   Boné, Beata ^a   Aspelin, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c Norra Alvsborg County Hospital Uddevalla   (Sweden)

Author keywords

Breast neoplasm; Histopathology; Malignancy grade; Technetium 99m sestamibi; Tumour to background ratio

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BODY POSTURE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT SELECTION; SCINTIMAMMOGRAPHY; SUPINE POSITION; TUMOR BIOPSY; TUMOR LOCALIZATION; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; VALIDATION STUDY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0038583785     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1132-2     Document Type: Article

References (22)

1. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999; 29:16-40.
2. Bonè B, Aspelin P, Bronge L, Veress B. Contrast-enhanced MR imaging as a prognostic indicator of breast cancer. Acta Radiol 1998; 39:279-284.
3. Donegan W. Staging and primary treatment. In: Donegan W, Spratt J, ed. Cancer of the breast, 4th edn. Philadelphia: Saunders; 1995:392-396.
4. Tavassoli F. Pathology of the breast. Connecticut: Appelton & Lange; 1992:36.
5. Boné B, Péntek Z, Perbeck L, Veress B. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol 1997; 8:489-496.
6. Bonè B, Aspelin P, Bronge L, Isberg B, Perbeck L, Veress B. Sensitivity and specificity of MR mammography with histopathological correlation in 250 breasts. Acta Radiol 1996; 37:208-213.
7. Villanueva-Mayer J, Leonard MH Jr., Briscone E, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37:926-930.
8. Bombardieri E, Crippa F, Maffioli L, Greco M. Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med 1997; 24:809-824.
9. Danielsson R, Boné B, Gad A, Sylvan M, Aspelin P. Sensitivity and specificity of planar scintimammography with 99mTc-sestamibi. Acta Radiol 1999; 40:394-399.
10. Mussurakis S, Buckley D, Horsman A. Dynamic MR imaging of invasive breast cancer: correlation with tumor grade and other histological factors. Br J Radiol 1997; 70:446-451.
11. Cwikla JB, Buscombe JR, Kolasinska AD, Parbhoo SP, Thakrar DS, Hilson AJ. Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer. Anticancer Res 1999; 19:2299-2304.
12. Elston CW, Ellis IO. Assessment of histologic grade. In: Elston CW, Ellis IO, eds. The breast. Systemic pathology, vol 13. Edinburgh New York: Churchill Livingstone; 1998:366-384.
13. Sánchez-Crespo A, Jonsson C, Pegerfalk A, Danielsson R, Aspelin P, Larsson S. Quantitative assessment of activity concentrations in small tumours using planar mammoscintigraphy. IFMBE Proceedings of the International Federation of Medical and Biological Engineering. Reykjavik. 2002; 2:88-89.
14. Contesso G, Mouriesse H, Friedman S, et al. The importance of histologic grade in long term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5:1378-1386.
15. Contesso G, Saccani Jotti G, Bonadonna G. Tumor grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 1989; 25:403-409.
16. Robbins S. The female breast. In: Robbins S, ed. Pathologic basis of disease. Philadelphia: Saunders; 1994:1103-1109.
17. Tabár L, Fagerberg G, Duffy S, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30:200-204.
18. Henson D, Ries L, Freedman L, Carragia M. Relationship among outcome, stage of disease, and histological grade for 22,616 cases of breast cancer. Cancer 1991; 68:2142-2149.
19. Buadu L, Murakami J, Muryama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathological findings and tumor angiogenesis. Radiology 1996; 200:639-649.
20. Stomper P, Herman S, Klippenstein D, et al. Analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. Cancer 1996; 77:1844-1849.
21. Scorpinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21:984-987.
22. Sánchez-Crespo A, Petersson J, Nyren S, Mure M, Glenny Robb W, Thorell J-O, Jacobsson H, Lindahl S, Larsson S. A novel quantitative dual-isotope method for simultaneous ventilation and perfusion lung SPET. Eur J Nucl Med 2002; 29:863-875.